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Structural Basis of Chemokine Sequestration
by a Herpesvirus Decoy Receptor
classified as CC, CXC, CX3C, and C based on the ar-
rangement of disulfide forming Cys residues at the N
terminus (Rollins, 1997). In general terms, chemokines
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Emory University ciations postulated to play roles in chemokine regula-
Atlanta, Georgia 30329 tion. Some reports suggest that chemokines necessarily
bind receptors as dimers (Leong et al., 1997; Zhang and
Rollins, 1995), and that receptor dimerization is required
for signal transduction (Mellado et al., 2001). Other stud-Summary
ies argue that chemokines bind and activate their recep-
tors in a monomeric form (Laurence et al., 2000; PaavolaThe M3 protein encoded by murine herpesvirus68
et al., 1998).(HV68) functions as an immune system saboteur by
Large DNA viruses have developed a number of strat-the engagement of chemoattractant cytokines, thereby
egies to evade host chemokine mediated immune re-altering host antiviral inflammatory responses. Here
sponses (Alcami and Koszinowski, 2000; Murphy, 2001).we report the crystal structures of M3 both alone and
One mechanism used by viruses to undermine chemo-in complex with the CC chemokine MCP-1. M3 is a
kine signaling is the production of altered versions oftwo-domain  sandwich protein with a unique se-
chemokines or chemokine receptors. For example, vi-quence and topology, forming a tightly packed anti-
rally encoded proteins may act as agonists or antago-parallel dimer. The stoichiometry of the MCP-1:M3
nists to endogenous chemokine receptors (Kledal et al.,complex is 2:2, with two monomeric chemokines em-
1997), or as constitutively signaling GPCRs (Arvanitakisbedded at distal ends of the preassociated M3 dimer.
et al., 1997). Another viral strategy is the secretion ofConformational flexibility and electrostatic comple-
high-affinity binding proteins that act as chemokinementation are both used by M3 to achieve high-affinity
scavengers. One such example is M-T7 protein fromand broad-spectrum chemokine engagement. M3 also
myxoma virus, which appears to function as both a solu-employs structural mimicry to promiscuously seques-
ble IFN- receptor and chemokine binding protein. M-T7ter chemokines, engaging conservative structural ele-
is thought to bind chemokines in a low-affinity, non-ments associated with both chemokine homodimer-
specific manner by interacting with their basic GAGization and binding to G protein-coupled receptors.
binding regions (Lalani et al., 1997). Another example
is the poxvirus p35(T1) family of secreted chemokine
binding proteins (Graham et al., 1997). These proteins
Introduction specifically bind CC chemokines with high-affinity and
inhibit both chemokine-induced signaling and leukocyte
Chemokines are a subset of cytokines principally re- chemotaxis. To date, the only structural characterization
sponsible for controlling leukocyte migration in the in- of a viral chemokine binding protein has been the cow-
nate immune response, as well as activation and devel- pox member of the p35 family, vCCI (Carfi et al., 1999).
opment processes in adaptive immunity (Rossi and The crystal structure of vCCI revealed a single-domain
Zlotnik, 2000). The known chemokine network is com- protein with a novel  sandwich topology, although it is
prised of more than 50 distinct chemokines that bind not presently clear how this protein sequesters CC-fam-
and transduce signals through 20 distinct members of ily chemokines.
the G protein-coupled receptor (GPCR) superfamily. The first secreted chemokine binding protein from a
Members of the chemokine superfamily are structurally herpesvirus, M3 from murine herpesvirus-68 (HV68),
has recently been reported (Parry et al., 2000; van Berkel
et al., 2000; Bridgeman et al., 2001; van Berkel et al.,7 Correspondence: fremont@pathbox.wustl.edu
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Table 1. Summary of Data Collection, Phasing, and Refinement
Data Collection for M3a
Space Group C2
Unit Cell (A˚3) a  140.9 b  67.3 c  93.9   120.4
Data Set Native HgCl2 PCMBS Pt(NO3)2
Wavelength (A˚) 1.100 1.5418
X-ray Source NSLS X25b Rigaku
Resolution (A˚) overall(outer shell) 20–2.1 (2.2–2.1) 20–2.7 (2.8–2.7) 20–2.7 (2.8–2.7) 20–2.7 (2.8–2.7)
Observations/Unique 133215/43484 98349/21110 87733/21220 101513/21239
Completeness (%) 98.0 (97.0) 99.2 (98.5) 100 (100) 99.4 (98.6)
Rsym (%) 5.2 (34.6) 6.8 (29.0) 7.4 (32.4) 5.9 (24.6)
I/ 20.4 (2.9) 24.2 (5.1) 20.5 (4.1) 28.0 (6.4)
MIR Phasing Statisticsc for M3
Heavy atom sites 10 6 4
Rcullis centric/acen 0.85/0.75 0.89/0.85 0.77/0.73
Phasing Power centric/acentric 1.07/1.45 0.70/1.03 1.22/1.59
Figure of Merit centric/acentric 0.71/0.49
Data Collection for SeMet M3-MCP-1 Complex
Space Group P321
Unit Cell (A˚3) a  b  99.2 c  78.9
X-ray Source NSLS X25
Data Set 1 2 3 4
Wavelength (A˚) 1.000 0.9796 0.9789 0.9599
Resolution (A˚) (outer shell) 20–3 (3.19–3) 20–3 (3.19–3) 20.–3 (3.19–3) 20–3 (3.19-3)
Observations/Uniqued 41932/16718 43014/16785 42994/16785 42964/16750
Completeness (%) 96.3 (94.4) 96.6 (94.8) 96.6 (94.8) 96.4 (94.7)
Rsym (%) 8.0 (28.6) 7.7 (25.7) 6.9 (17.8) 7.5 (21.5)
I/ 10.4 (3.2) 10.8 (3.7) 11.8 (6.2) 11.2 (4.7)
MAD Phasing Statistics for SeMet M3-MCP-1 Complex
Anomalous Scatterer 13 Se
Resolution (A˚) 20–3.0
Rcullis centric/acentric 0.93/0.94 0.57/0.74 0.78/0.89 —
Anomalous Rcullis 0.91 0.76 0.72 0.78
Phasing Power centric/acentric 0.73/0.64 1.52/1.33 0.79/0.74 —
Anomalous Phasing Power 0.82 1.40 1.49 1.26
Refinement Summarye M3 SeMet M3-MCP-1 Complex
Resolution (A˚) 20–2.1(2.2–2.1) 20–2.8(2.97–2.8)
Reflections Rwork/Rfree 38527/2506 10335/569
#Protein Atoms/Solvent 5706/332 2853/43
Rwork overall(outer shell) (%) 22.8(32.3) 20.1(32.4)
Rfree overall(outer shell) (%) 27.3(36.4) 28.2(37.1)
Rmsd Bond lengths (A˚)/angles () 0.006/1.4 0.008/1.4
Rmsd Dihedral/Improper () 26.0/0.79 25.7/0.87
Ramachandran plot
Most favored/Additional (%) 87.2/12.3 85.5/14.5
Generous/Disallowed (%) 0.5/0.0 0.0/0.0
Domain B-values (A˚2) A-NTD  45.6/B-NTD  45.7 NTD  63.2/CTD  60.2
A-CTD  43.5/B-CTD  66.5 MCP-1(P8A)  70.0
a Values as defined in SCALEPACK (Otwinowski and Minor, 1997).
b National Synchrotron Light Source, Beamline X25.
c Values as defined in MLPHARE (CCP4, 1994).
d Unique reflections for individual wavelengths include unmerged-Bijvoet pairs.
e Values as defined in CNS (Brunger et al., 1998).
2002). HV68 is a natural pathogen of rodents (Blaskovic tionally, M3 can potently and specifically block chemo-
kine-mediated calcium mobilization in receptor bearinget al., 1980) closely related to KSHV and EBV (Virgin et
al., 1997). The M3 ORF encodes an abundantly secreted cells in vitro. Recent analyses of the effect of a disrupted
M3 gene on HV68 pathogenesis has revealed a critical42 kDa protein that acts as a broad-spectrum chemo-
kine scavenger, readily forming complexes with all mu- role of M3 in virulence and the nature of virally induced
inflammation in vivo (van Berkel et al., 2002).rine and human CC, C, and CX3C chemokines tested
to date. However, within the CXC family, M3 displays We present here structural and in vitro functional stud-
ies of M3. The crystal structure of M3 reveals a novelselectivity in its binding to individual members. Func-
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structure that tightly associates as an anti-parallel di- The CTD is most similar to the V domain of monoclonal
antibody se155-4 (PDB code 1MFA) (rmsd  3.7 A˚ former. The complex of M3 with the CC-chemokine MCP-1
discloses a 2:2 binding stoichiometry, with two distinct 101 aligned residues, with 5% sequence identity). The
CTD is distinct from a canonical V-type Ig-fold as therebinding sites at opposite ends of the M3 dimer. These
structural studies, combined with further biophysical are additional  strands on each face of the sandwich,
one adjacent to the G-strand (denoted A″), and oneand mutational analysis, brings to light an atomic view
of how this viral decoy receptor accomplishes the task of neighboring the A-strand (denoted A). The M3 CTD has
three large loops that extend from the sandwich, (A″-promiscuous yet high-affinity chemokine sequestration.
A, A-B, and C-C). There are three disulfide bonds in
Results the M3 CTD, two connecting the A″-A loop to the A-B
loop and one connecting the C″-D loop to the long C
Structural Description of M3 strand. In the M3 CTD, the canonical Ig disulfide be-
The structure of HV68 M3 was determined by MIR and tween the B and F strands is absent, and instead is
refined at 2.1 A˚ resolution (Table 1). M3 adopts a two replaced by hydrophobic interactions between adjacent
lobed structure, with the N-terminal domain (NTD) and Leu residues.
C-terminal domain (CTD) each composed of an ex-
tended  sandwich decorated by several large loops M3 Dimerization
and helical segments (Figure 1A). We detected no two- The crystal structure of M3 is a tightly associated anti-
domain structures similar to M3 in the fold classification parallel homodimer created by a non-crystallographic
databases, though both domains do distantly resemble 2-fold axis (Figure 1A). This places the NTD of one sub-
previously reported folds. M3 forms an asymmetric di- unit adjacent to the CTD of the other. Asymmetry arises
mer, with two M3 chains pairing in an anti-parallel fash- where the NTD faces the opposite CTD; the position of
ion to create a flat, rectangular complex. loops and orientation of domains are altered, resulting
in two different conformations at opposite ends of the
Architecture of the N-Terminal Domain (NTD) dimer. Long loops extend from each domain to form the
The M3 NTD spans residues 1–210 and is a  sandwich dimeric interface, with the NTD domain interacting with
composed of 5-stranded and 8-stranded  sheets (Fig- both domains of the opposite monomer. Homodimer
ure 1B). There are two disulfide bonds in the NTD, one interactions in M3 are dominantly mediated by the s3-
located between the h1 and h2 helices and another s4, s7-s8, and s5-s6a loops of the NTD subunit and the
linking the large s1-s2a loop to s10 of the core  sand- long C- C loop of the CTD subunit, which stretches and
wich. One of the more striking features of the NTD is grasps the NTD of the adjacent monomer. The dimer
the adjacent extension of three highly acidic, solvent- interface is composed of a mix of polar and hydrophobic
exposed loops (s2b-s3, s4-s5, and s8-s9) from the end interactions, with approximately 3200 A˚2 of solvent ac-
of the  sandwich. The topology of the NTD displays cessible surface buried. The buried dimer interface is
similarity to a number of reported protein structures; the comprised of 31 residues per monomer, with 21 in the
most similar of which is the C-terminal receptor binding NTD and 10 in the CTD.
domain of diphtheria toxin (DT) (PDB code 1DDT). De-
spite displaying only 6% sequence identity, strands s3
Structural Description of M3 in Complexthrough s10 in the core of the NTD are analogous to
with MCP-1(P8A)strands R3-R10 of DT, in both position and connectivity
In order to ascertain the mechanism of chemokine bind-(rmsd  3.9 A˚ for 111 aligned residues). However, the
ing by M3, we initiated cocrystallization experimentsregion in which these two proteins display the greatest
using a monomeric variant of human MCP-1 (Paavolastructural differences corresponds to the receptor bind-
et al., 1998). Baculovirus-mediated production of SeMeting surface of DT (Louie et al., 1997). The analogous
incorporated M3 enabled experimental MAD phasingregion of M3 is sterically occupied by three  helices
of the M3/MCP-1(P8A) complex, with the final atomicinserted between the N-terminal s1 and s2b  strands.
model refined to 2.8 A˚ resolution (Table 1). In the com-The core of the NTD also displays remote structural
plex, M3 forms a symmetric homodimer similar to thatsimilarity to the cowpox virus chemokine binding protein
observed for the unliganded protein, with two chemo-vCCI (PDB code 1CQ3) (Carfi et al., 1999) (rmsd  3.5 A˚
kines bound into niches at distal ends of the dimer (Fig-for 79 aligned residues with 3% sequence identity). In
ure 2B). Thus, MCP-1(P8A) binds to M3 as a monomergeneral, both structures are composed of a core  sand-
in a 2:2 stoichiometry, with no interactions observedwich, each uniquely decorated with loops and helices.
between the two chemokines.While the majority of the  strands in the core of M3 have
analogous strands in vCCI, the connecting topology of
Architecture of the Chemokine Binding Cleftthe two structures appears completely distinct. The
The chemokine binding sites of M3 are deep clefts formedcrystal structure of vCCI revealed a potential dimeric
between the NTD and CTD  sandwiches (Figure 2D).association, although the protein has been reported to
There are 26 residues from MCP-1(P8A) and 29 residuesform a 1:1 complex with chemokines in solution (Carfi
from M3 at each ligand-receptor interface, which is com-et al., 1999).
prised of 2000 A˚2 of buried solvent accessible surface area
(1.4 A˚ probe) (Brunger et al., 1998). The shape complemen-Architecture of the C-Terminal Domain (CTD)
tarity at the M3/MCP-1 interface is calculated to be Sc The CTD encompasses residues 211–382 and adopts a
 sandwich fold similar to a V-type Ig-fold (Figure 1C). 0.62 (Lawrence and Colman, 1993). The chemokine bind-
Cell
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Figure 1. Structure of the HV68 M3 Homodimer
(A) Ribbon diagram of the asymmetric, anti-parallel M3 homodimer. The two monomers are displayed in cyan/blue and magenta/red coloring
for their N-terminal domain (NTD) and C-terminal domain (CTD), respectfully.
(B) Ribbon diagram of the N-terminal  sandwich domain of M3, residues His12-Ser210.  strands are depicted in green,  helices in cyan,
310 helices in blue, connecting loops in orange, and disulphide bonds in yellow. In the middle is the structure of the receptor binding domain
of diphtheria toxin (pdb entry 1DTT), and to the right is the similar structure but distinct folding topology of the poxvirus chemokine binding
protein VCCI (1CQ3).
(C) Ribbon diagram of the C-terminal domain of M3, residues Leu211-His382. Compared at right is a typical V-type Ig-fold from an antibody
V-domain (1CID).
ing surface is equally distributed between the two sub- additional roles played by the s4-5 and s8-9 strands and
loops (Figure 2). Nine NTD residue side-chains makeunits of M3; sixteen residues in the NTD and 13 in the
CTD lose surface accessibility upon complex formation direct contact (	4 A˚) with MCP-1, while 16 lose appre-
ciable solvent accessible surface area and are high-(Figure 2C). The MCP-1 binding interface includes the
N terminus, the entire N-loop, and to a lesser extent, lighted as magenta filled circles in the sequence annota-
tion of Figure 2C. Generally, the cleft region createdthe 30’s loop, 40’s loop, and the C-terminal helix. As
can be seen in the schematic Figure 2A, the NTD forms by the NTD is extremely rich in acidic residues, which
complements the highly basic MCP-1. For example, thethe portion of the binding site that contacts the latter
part of the chemokine N-loop, 40’s loop, and C-terminal acidic s2b-s3 loop is located proximal to MCP-1 resi-
dues R24 and R49, while acidic residues on the s5 andhelix, while the CTD of M3 contacts the N terminus, the
first part of the N-loop, and the 30’s loop. s8 strands are adjacent to MCP-1, R18, and K19. How-
ever, it is clear that chemokine interactions with the
NTD involve more than just electrostatics, as extensiveChemokine Interactions with the NTD Subunit
The primary structural element used by the NTD to cre- hydrophobic contacts utilizing L82, Y125, Y127, and
L174 of M3 are also observed.ate the chemokine binding cleft is the s2b-3 loop, with
Mechanism of Herpesvirus Chemokine Sequestration
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Chemokine Interactions with the CTD Subunit a hydrodynamic radius of 42 A˚ corresponding to a calcu-
lated molecular weight of 96 kDa for a spherical, globularThe primary structural element of the CTD used to bind
chemokine is the A-B loop, which includes the h6 helix protein (Figure 3C). In addition, the radius predicted by
DLS closely matched half the distance between the twoand B-strand depicted in Figure 2. Most notable is the
formation of an anti-parallel  strand interaction be- most distant points in the dimeric M3 crystal structure
(46 A˚). Similar DLS experiments were carried out to de-tween M3 residues 273–275 (the B-strand) and N-ter-
minal MCP-1 residues 10–12. In addition to the main termine the oligomeric state of M3 complexed with che-
mokine. The data from M3 complexed with both MCP-1chain interactions, M3 P272 packs tightly against the
chemokine invariant C12-C52 disulfide, while M3 A275 and MCP-1(P8A) fit best to a monomodal distribution
of particles with a hydrodynamic radius of 41 A˚ andinteracts with the C11-C36 disulfide. In total, six side
chains of the CTD make direct contact with MCP-1. Of 40 A˚, respectively. The frictional coefficient F  RDSL/
RSPH was calculated as 1.45 for the M3 dimer and 1.33further note is a hydrophobic pocket formed by the A″-
A, A-B, and E-F loops of M3 which serves to sequester for the M3/MCP-1(P8A) complex, consistent with the
flat rectangular shapes of the crystal structures. TheseMCP-1 Y13, a critical residue for GPCR binding and
signaling (see below; Jarnagin et al., 1999). results further support the crystallographic observation
that M3 exists as a dimer both free and bound to che-
mokine.Structural Differences between M3 Alone
and the M3/Chemokine Complex
Comparison of M3 free and bound to chemokine indi- Chemokine Binding Stoichiometry
cates significant conformational variation associated Complexes prepared at differing molar ratios were ex-
with ligand binding. As seen in Figure 2D (left image), amined on native PAGE to determine whether stable
the chemokine binding sites in the uncomplexed M3 intermediates could be observed (Figure 3B). This ex-
dimer are asymmetric, with one binding site resembling periment clearly shows a third species present under
the open chemokine-complexed conformation and the conditions of excess M3, with a molecular weight be-
other more tightly closed due to the interaction of the tween the species observed in excess chemokine and
loops across the opposing NTD and CTD modules. The that of unbound M3. Identical results were obtained for
conformational differences include loop remodeling as complexes formed between M3 and MCP-1(P8A) (data
well as domain movements of approximately eight de- not shown). The three bands observed on the native gel
grees for one M3 monomer relative to the other in the represent unbound M3, a single bound intermediate in
homodimer (Figure 2D, middle image), although small excess M3 with a ratio of 1:2 MCP-1 to M3, and fully
movements of all four domains can be detected (Hay- formed complex in excess MCP-1 with a ratio of 2:2.
ward and Berendsen, 1998). Inspection of the crystal The appearance of the stable intermediate suggests that
lattice differences between M3 alone and the M3/MCP- M3 does not exhibit a high degree of positive cooperativ-
1(P8A) complex does not reveal any obvious packing ity in binding chemokines at two distinct sites.
artifacts that would explain the different quaternary
structures we observe.
Binding Analysis of Mutant Chemokines
To validate the interactions we observed between M3Solution and Mutational Analysis
and MCP-1(P8A), Ala mutants of residues Y13, K19, R29,To confirm and extend our structural observations, we
I46, and E50 of MCP-1 were tested for their ability toundertook biophysical and mutational studies to exam-
competitively bind M3 using our previously reportedine the oligomeric state of M3 in solution, the stoichiom-
assay (van Berkel et al., 2000; Figure 3D). Tyr13 and K19etry of chemokine engagement, and the role of specific
of MCP-1 directly contact M3 in the complex, while E50MCP-1 residues in high-affinity complex formation.
loses only a small amount of solvent-accessible surface
area. R29 and I46 are outside the binding interface but
Oligomeric Association in Solution
form interactions with a symmetry-related M3 molecule
To address whether M3 exists as a dimer in solution,
in the crystal structure, and therefore serve as important
analytical size exclusion chromatography (SEC) was
controls. The results of these binding studies show that
carried out with M3 alone and in complex with MCP-1
only substitutions of Y13 and, to a lesser extent, K19,
(Figure 3A). M3 alone eluted as a single peak with an
had a measurable effect on binding affinity. The Y13A
apparent molecular weight of 100 kDa, suggesting that
variant had a greater than 10-fold decrease in apparent
the 42 kDa M3 exists as a dimer in solution. Experiments
binding affinity, while K19A binding was diminished
using M3 mixed with molar excess of MCP-1 resulted
2-fold. Taken together, these solution and mutational
in a peak corresponding to a calibrated molecular weight
experiments convincingly validate our crystallographic
of 122 kDa, which we interpret as a 2:2 complex of
observations.
M3:MCP-1 (calculated MW of 100.8 kDa). Experiments
using M3 and the MCP-1(P8A) variant yielded an esti-
mated MW of 119 kDa for the complex. Thus, the SEC Analysis of Chemokine Binding Selectivity
and Promiscuityresults are congruent with our structural observations
that M3 is dimeric both free and in complex with che- In order to address the structural basis of chemokine
functional inhibition by M3, we undertook a comparativemokine.
To further characterize the solution behavior of M3, analysis of the residues of MCP-1 that are engaged in
the complex. We then analyzed other binding and non-dynamic light scattering experiments (DLS) were under-
taken. Monomodal analysis of a pure M3 solution yielded binding chemokine family members by aligning their se-
Cell
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Figure 2. Structure of the M3/Chemokine Complex
(A) Secondary structure cartoon of the M3/chemokine complex. A schematic of a M3 monomer is displayed with the same secondary structure
coloring as (B). The CC chemokine MCP-1 is diagramed in magenta. Regions of M3 that interact with chemokine are highlighted with magenta
arrows; M3 dimer interaction regions are indicated in gray. The location of disulphide bonds in M3 are indicated by black sequence numbers
and dashed lines.
Mechanism of Herpesvirus Chemokine Sequestration
349
quences and available structures in the context of our spite their overall sequence diversity. Nevertheless, dif-
ferences are observed in the N-loop that may provideMCP-1/M3 complex.
some clues toward specificity (Figure 4C). For example,
the center of the N-loop of non-binding CXC-chemokinesAnalysis of the MCP-1 Contact Surface
appear to commonly pack closer to the C-terminal heli-Figure 4A depicts the large interface of MCP-1 that is
cal region as a result of a deletion at the position corre-grasped by M3, which includes 26 different residues
sponding to MCP-1 R18. In contrast, the N-loops of M3that become buried in the complex. The M3 NTD and
binding chemokines bulge relatively outward, where resi-CTD subunits each directly contact seven MCP-1 side
dues 17–19 of MCP-1 protrude and interact with the M3.chains, which are localized to two distinct patches on
The single invariant aspect of the sequences pre-the primary binding face of the chemokine (Figure 4B).
sented in Figure 4D is the chemokine defining C12-C52The NTD engaged patch is primarily composed of basic
disulfide, which is engaged by the M3 A-B loop.N-loop residues while the CTD engaged patch is cen-
Amongst the other M3 interacting residues in MCP-1,tered on the N-terminal disulfide bonds and includes
only two are highly conservative among the binding se-basic 30’s-loop residues. The 40’s-loop, implicated in
quences, I20 located in the NTD contact patch, and I42GAG binding for most chemokines including MCP-1,
situated above the C12-C52 disulfide in the CTD contactis situated between and contributes to both contact
patch. Non-binding chemokines also maintain Ile or Valpatches, but yet maintains solvent accessibility. Re-
at these two positions. Our Ala mutation of MCP-1 N-loopmarkably, the MCP-1 surface engaged by M3 contains
residue Y13 revealed an important role of this aromaticprecisely the same residues that were previously identi-
residue in M3 binding, and indeed the highest affinityfied by mutational analysis as important endogenous
chemokines have a Y or F in this position. Other MCP-1receptor CCR2b contacts (Hemmerich et al., 1999). Spe-
interface residues that are frequently similar in othercifically, substitutions of MCP-1 residues Y13, R24, K35,
binding chemokines include two hydrophobic residuesK38, and K49 with Ala each decrease CCR2b binding
(I51 and W59) and seven basic residues (R18, K19, R24,affinity greater than 10-fold. R24 and K49 are part of the
K35, K38, K49, and K58). However, in no case are theseNTD contact patch, while Y13, K35, and K38 abut CTD
residues uniformly present in binding chemokines or ab-loops. MCP-1 N-terminal residues 1–7, essential for en-
sent from non-binding chemokines. Thus, our analysisdogenous receptor signaling (Jarnagin et al., 1999), were
of the M3/MCP-1 contact surface has revealed severalnot visible in our structure and are presumptively not in
general features associated with promiscuous chemo-contact with M3. Regardless, M3 sequestration renders
kine binding, although at present no defining chemokinethis region inoperative as M3 potently blocks MCP-1
sequence motifs uniquely responsible for selective high-mediated calcium flux within macrophages (van Berkel
affinity M3 engagement are apparent.et al., 2000). Thus, M3 acts as a competitive receptor
mimic despite a lack of apparent similarity to the cellular
7 transmembrane GPCRs. Discussion
Enabled by their relatively large genomic coding capac-Sequence and Structural Comparison
of the Chemokine Contact Surface ity, poxviruses and herpesvirus have evolved a myriad
of different proteins capable of undermining innate andWhile 11 different CC, C, and CX3C chemokines tested
for M3 binding demonstrate nanomolar affinities, M3 adaptive immune communication pathways. Cytokine
decoy receptors encoded by these viruses tend to beengages members of the CXC chemokine family with
lower affinity and apparently higher selectivity. Indeed, stolen variants of host receptors, often modified to allow
for secretion from infected cells. Because chemokineonly 4 of 12 CXC chemokines have been characterized
as M3 binders (IL8, hIP10, mMIG, and mBCA1; Figure signaling occurs through a large family of 7-pass trans-
membrane GPCRs expressed on diverse cell types that,4D). With the exception of the flexible N- and C-terminal
segments of the chemokines, the structures of binding for obvious physical reasons, do not occur in soluble
form, viruses must develop alternate mechanisms toand non-binding chemokines are remarkably similar de-
(B) Ribbon diagram of the M3/chemokine complex. The M3 monomer on the left is colored and labeled as in (A), the monomer on the right
is colored cyan, and the two MCP-1(P8A) monomers are colored magenta.
(C) M3 sequence analysis. Displayed is the sequence of M3 aligned with HV68 M1 and M4, the only known proteins with appreciable sequence
similarity to M3. Dominantly inaccessible residues of M3 are underscored with gray (
80% buried). Magenta circles denote M3 chemokine
binding interface residues. Residues buried in the M3 dimer interface have black filled triangles, while residues at the NTD-CTD interface of
a single monomer have upward pointing open triangles. Residues buried both in the dimer interface and the NTD-CTD interface have upward
pointing filled triangles. The predicted mature M1 and M4 sequences (after signal cleavage) have been aligned to M3 based on the burial of
core hydrophobic residues, Cys placement, and location of possible N-linked glycosylation sites (underlined) away from core folding elements.
This analysis indicated that M1 and M4 might share folding features with M3, although at present the function of neither protein is known.
Nevertheless, since few of the M3 homodimer interface or chemokine contact residues are conserved between M3 and either M1 or M4, these
proteins may well assume oligomeric assemblies and functional roles completely distinct from M3.
(D) The uncomplexed M3 homodimer is displayed as individual solvent accessible surfaces with blue and cyan monomers. The preassociated
M3 dimer assumes an asymmetric conformation with one chemokine binding cleft open (at top) and one apparently closed (at bottom).
Displayed in the middle are the superimposed free (gray) and liganded (blue, cyan, and magenta) M3 structures. The approximate domain
movements of M3 subunits from free to bound conformations are depicted as arrows. At right is a surface depiction of the symmetric M3/
MCP-1(P8A) complex, with the two chemokines buried at distal clefts of the M3 dimer seen in magenta.
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Figure 3. Experimental Validation of Crystallographic Observations
(A) Size Exclusion Chromatography (SEC) analysis of M3 and M3/chemokine complexes. SEC was used to determine the apparent size of
M3 alone (depicted in green), and in complex with MCP-1(wt) (blue) or the mutant MCP-1(P8A) (black). M3 complexes were loaded with a
4-fold molar excess of chemokine. The elution volume of M3 is consistent with the interpretation that the protein exists as a tightly associated
dimer, and the elution volume of the M3/MCP-1 mixtures suggests that the complex contains two molecules of each M3 and MCP-1. Molecular
weights were estimated based on a calibration curve (on the right) generated from the averaged elution of five standardized proteins run
three times (depicted in red).
(B) Native PAGE analysis of M3/MCP-1 complexes. Samples containing varying molar ratios of M3 and MCP-1(wt) were run on native PAGE.
Three bands were observed representing the unliganded M3 alone, single-liganded M3, and double-liganded forms of the M3 dimer, as
schematically depicted in (C).
(C) Summary of M3 solution analysis. SEC and dynamic light scattering (DSL) experimental results are compared to protein sequence calculated
molecular weights (Calc) and atomic model sizes (X-ray radii). Where appropriate, both MCP-1(wt) and MCP-1(P8A) results are presented.
(D) Binding of MCP-1 variants to M3. Competitive inhibition binding to M3 was investigated for several Ala substituted mutants of MCP-1.
The percentage of maximal binding (mean  SEM) refers to binding in the absence of competitor. On the right, a ribbon diagram of MCP-
1(P8A) is shown highlighting the side chains of the mutated residues (in magenta). MCP-1 residues Y13 and K19 directly contact M3 in the
complex crystal structure, and their substitution with Ala decreases their binding capacity. The other three residues (R29, I46, and E50) are
located more distal from the M3 interface and their Ala substitution has little effect on binding.
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Figure 4. Analysis of Chemokine Binding Specificity and Promiscuity
(A) M3 engagement of MCP-1(P8A). Displayed is the chemokine surface with residues making direct contact (	4.0 A˚) with M3 NTD labeled
in blue (at left) and with M3 CTD in cyan (at right). Additional interfacial residues that lose solvent accessible surface area in the complex are
colored magenta. Loops from the M3 NTD and CTD domains that form the chemokine binding cleft are displayed as yellow tubes, as are the
side chains of M3 direct contact residues.
(B) Ribbon diagram indicating the MCP-1 residues specifically engaged by M3, oriented and colored as in (A).
(C) N-loop regions of representative binding and non-binding chemokines structures superimposed on MCP-1(P8) as oriented as in (B). Tube
representations of M3 binding CC-chemokines hMIP (1B53) and hRANTES (1B3A) are in cyan as are the C-chemokine hLymphotactin (1J90)
and CXC-chemokine IL-8 (3IL8). The N-loop regions of the non-binding CXC chemokines hGRO (1MSG), mMIP2 (1MI2), and hSDF-1 (1QG7)
are displayed in yellow.
(D) Chemokine sequence analysis. Chemokine sequences tested for M3 binding in two different assays have been structurally aligned, with
class-defining Cys residues boxed. Presented are competitive inhibition binding affinities (van Berkel et al., 2000) and our scoring of results
from a chemical crosslinking based assay (Parry et al., 2000). Blank lines indicate not tested and (
1000) and (-) indicate undetected
associations. PDB codes are indicated for known structures, with these same coordinates depicted in (C). Side chains that make direct contact
(	4 A˚) with M3 are highlighted in blue (NTD contacts) and cyan (CTD contacts). Additional residues that lose any solvent accessible surface
area in the complex are highlighted with magenta. Residues invariant among the binders (upper sequences) or non-binders (lower sequences)
are indicated by filled triangles pointing down or up, respectively. Conservatively substituted positions are indicated with open triangles.
disrupt chemokine gradients. The structural and bio- (Garcia et al., 1999; Sundberg and Mariuzza, 2000). In
our structural analysis, the binding of chemokines ischemical results presented here for the HV68 M3 decoy
receptor detail precisely how it accomplishes the task associated with M3 domain rearrangements and the cre-
ation of distinct geometries for the chemokine bindingof high-affinity, broad-spectrum sequestration of che-
moattractant cytokines. Mechanistically, M3 appears to clefts, raising the possibility that M3 could form alternate
binding site configurations to optimally accommodateestablish promiscuous recognition of members of all
four chemokine families through the use of conforma- ligands with similar folds but highly variable sequences.
Thus, promiscuous chemokine binding by M3 may betional plasticity and electrostatic complementation. Fur-
ther, despite the lack of any sequence similarity to host attributed in part to the oligomeric construction of the
combining sites and the use of flexible loops as primaryassociated proteins, our structural results indicate that
M3 has evolved a mode of ligand sequestration that contact regions, a design highly reminiscent of adaptive
immune receptors that likewise use loops projectingappears to faithfully mimic the strategies employed in
cognate receptor binding. from two  sandwich folds to create ligand binding
niches. Interestingly, the loops used by the Ig-fold of
Structural Plasticity and Promiscuous the M3 CTD for chemokine binding are at the opposite
Chemokine Binding end of the domain relative to the CDRs of antibodies
A recurring hallmark of molecular recognition is the use and TCRs (Figure 1C), although cytokine receptors such
of receptor conformational plasticity to enable the bind- as EPO-R and hGH-R do utilize these “back-side” loops
(de Vos et al., 1992; Livnah et al., 1996).ing of vast numbers of morphologically diverse ligands
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Figure 5. Promiscuous Chemokine Binding Facilitated by M3 Conformational Plasticity and Electrostatic Complementation
(A) Comparison of the chemokine binding clefts of M3 alone and the M3/MCP-1 complex. The top image depicts the open and closed niches
found in the preassociated asymmetric homodimer, viewed looking edgewise into the binding sites. Chemokine contact residues highlighted
in blue (CTD) and cyan (NTD) and the corresponding loops that create the binding cleft are labeled. The middle image is a cartoon depicting
the asymmetric conformation of M3 alone and the symmetric dimer formed in complex with chemokine. Below is the edgewise view of the
M3 chemokine binding cleft with MCP-1 bound, depicted in magenta.
(B) Electrostatic complementarity between M3 and chemokines. On the right is the surface electrostatic potentials of the asymmetric M3
dimer (upper image) and the symmetric M3/MCP-1(P8A) complex (lower image). The view is rotated 90 relative to the edgewise orientation
seen in (A). Negative and positive electrostatic potentials are mapped to the surfaces in red and blue for  15 KeV using GRASP. In the lower
image, M3 and the chemokines are pulled apart to show their matched surfaces and charge potentials.
M3 Electrostatic Complementation tations (Sheinerman et al., 2000). M3 is an extremely
acidic protein (pI 4.2), with an especially significant clus-with Chemokines
Electrostatics play an important role in molecular recog- tering of acidic residues on the loops projecting from
the NTD (Figure 5B). In contrast, chemokines harbornition by enhancing the association rate of proteins and
allowing opportunities to achieve proper binding orien- significant clusters of basic residues on their surface in
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Figure 6. Structural Mimicry of Chemokine Dimer Formation and GPCR Receptor Binding
(A) Tube and surface representations of the M3 sequestration of MCP-1(P8A). M3 NTD and CTD loops are depicted in cyan, and the chemokine
in magenta. Cys residues are in yellow. Directly below is the same view depicting the MCP-1 (P8A) surface engaged by M3, with the intensity
of the magenta surface increased for shorter contact distances between 2.5 and 4 A˚. The acidic NTD s2b-s3 loop, which engages the N-loop
region, and the CTD A-B loop, which forms an anti-parallel  interaction with the N-terminal segment of MCP-1, are shown as cyan tubes
with their side chains displayed.
(B) CC-chemokine homodimerization as observed for MCP-1 (1DOK). Displayed is the homodimer of MCP-1 with the magenta monomer
oriented as MCP-1(P8A) in (A). The dimer is formed dominantly by the anti-parallel  interaction between N-terminal regions. Below is the
contact surface, highlighting the role of MCP-1 Pro8, which is situated above the chemokine invariant Cys12-Cys52 disulfide bond in precisely
the same location as M3 ProP272 in the M3/MCP-1(P8A) complex.
(C) Displayed is the NMR structure of dimeric IL-8 in complex with a modified peptide from the N terminus of the IL-8 receptor CXCR-1 (1ILQ).
The CXC dimer is displayed in magenta and blue and is formed through the extended sheet formed between monomer 1-strands. The
CXCR-1 receptor fragment also binds to the N-terminal chemokine region in an anti-parallel fashion, with Pro29 similarly packed on top of
the Cys12-Cys52 disulfide bond. Further, this receptor fragment also engages the N-loop region with a highly acidic cluster of residues, very
similar in location to where the M3 NTD s2b-s3 loop engages MCP-1(P8A).
order to interact with extracellular matrix GAGs. MCP-1 Structural Mimicry of Chemokine Self-Association
Based on known structures, MCP-1, like many CC che-(pI 9.4) has basic patches localized to the N-loop, 40’s
loop, and C-terminal regions situated directly opposite mokines, form dimers in an anti-parallel  strand ar-
rangement between the two flexible N termini (Figurethe M3 NTD. Given these features of the M3-MCP-1
complex, we envision that the initial interaction of che- 6B). Solution studies have provided dissociation con-
stants for several CC chemokine homodimers in the lowmokines with M3 could involve the electrostatic at-
traction of the acidic NTD loops. This interaction pre- micromolar range (Laurence et al., 2000; Paavola et al.,
1998). The interactions observed in the M3/MCP-1 com-sumably increases the on-rate for complex formation,
allows time for chemokine dimer dissociation if neces- plex suggest that M3 CTD has evolved the ability to
structurally mimic MCP-1 homodimerization in two im-sary (see below), and also allows time for the dominantly
hydrophobic CTD/chemokine contacts to form. This is portant ways. First, an anti-parallel  strand is formed
between the M3 CTD and the chemokine N-terminalconsistent with the idea that electrostatics drive the
kinetic rather than the thermodynamic association of strand. Further, M3 Pro272 packs against the chemokine
invariant disulfide bond in precisely the same way thatthese proteins, a hypothesis that still needs to be experi-
mentally addressed. Nevertheless, a significant aspect MCP-1 Pro8 packs against this same disulfide in the
MCP-1 dimer. In fact, Pro8 in MCP-1 is a critical residueof M3 chemokine binding promiscuity can be ascribed
to the high degree of electrostatic complementarity be- for the stabilization of the chemokine homodimer, al-
though it appears to have no role in receptor activationtween the surfaces engaged during complex formation,
as the frequency of their interactions is certainly aug- (Paavola et al., 1998). These molecular interactions thus
explain why MCP-1 binds M3 as a monomer, as chemo-mented.
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yeastolate (HyClone, Logan UT). M3 was purified to homogeneitykine dimerization and M3 binding appear mutually ex-
from cell supernatants using Q-Sepharose anion exchange chroma-clusive.
tography and size exclusion chromatography run on an AKTA FPLC
system. Electrospray mass spectroscopic analysis (Yale University)
Structural Mimicry of G-Protein Coupled revealed a primary peak at 41,785 daltons, indicating signal cleavage
Receptor Binding after residue 24 of the 406 amino acid M3 and the formation of 5
Our analysis indicates that M3 engages precisely the disulfide bonds.
SeMet labeled baculovirus M3 was produced following similarsame residues of MCP-1 that have been implicated in
methods as previously described (Fremont et al., 1998). The initialCCR2 receptor binding. The chemokine N terminus and
viral infection was performed in serum-free CCM3 medium lackingN-loop regions engaged by M3 are in fact generally essen-
yeastolate. At 24 hr post infection, Sf9 cells were harvested, washed,
tial features for specific receptor binding (Laurence et al., and transferred to serum-free CCM3 medium lacking both yeasto-
2000; Pakianathan et al., 1997). Thus, despite any se- late and methionine (HyClone). SeMet (Sigma, St. Louis, MO) was
quence identity to GPCRs, M3 structurally mimics che- added to a final concentration of 50 mg/liter and the culture contin-
ued for 6 days. The culture supernatant was harvested and themokine receptors, thereby functioning as a true decoy
secreted SeMet-M3 purified as described above.receptor. Interestingly, a recent study indicates that the
vaccinia virus chemokine decoy receptor likewise en-
Crystallization and Structure Determination of M3gages MCP-1 residues essential for endogenous recep-
Hanging-drop vapor diffusion using M3 at 13–15 mg/ml with 18%tor binding (Seet et al., 2001). Thus, it appears that unre-
PEG4000, 100 mM CaCl2, and 100 mM imidazole/malic acid [pH 5.1]lated proteins encoded by unrelated viruses can use the produced crystals in space group C2. Diffraction data for heavy
same general strategy of receptor mimicry. The advan- atom derivatives using PCMBS (10 mM, 2 hr soak), HgCl2 (10 mM,
tage of direct mimicry to competitively inhibit cellular 2 hr soak), and Pt(NO3)2 (10 mM, 9 hr soak) were collected using a
Rigaku X-ray source and an R-axis IV image plate detector. High-function has also been well established in the realm of
resolution native data were collected at beamline NSLS X25 (Brook-bacterial pathogenesis (Stebbins and Galan, 2001).
haven National Laboratory). Data were indexed and processed usingThe correlation between the M3 binding interface and
DENZO and SCALEPACK (Otwinowski and Minor, 1997; Table 1).the chemokine receptor binding site is further supported
Initial heavy atom positions were determined by Patterson methods
by the structure of IL-8 in complex with a modified and positions were refined using MLPHARE (CCP4, 1994). The qual-
N-terminal fragment of the IL-8 receptor, CXCR-1 (Skel- ity of the resulting MIR 2.7 A˚ experimental map was significantly
ton et al., 1999) (Figure 6C). The surface of IL-8 engaged improved by solvent flattening combined with NCS averaging using
DM. The initial model was traced into electron density maps dis-by this peptide mimic shares a striking similarity to that
played using the program O (Jones et al., 1991). Several iterativeengaged by M3. The use of structural mimicry by M3 is
steps of model building were carried out with phase-combined mapsfurther evident in the acidic nature of the CXCR-1 de-
and atomic refinement using CNS (Brunger et al., 1998). The finalrived peptide and in the positioning of P29, which inter-
stages were done in the absence of NCS averaging, as there are
acts directly with the chemokine invariant disulfide ex- significant differences between the two M3 monomers in the asym-
actly coincident with the position of P272 from the M3 metric unit (rmsd of 1.0 A˚ for all atoms, 0.72 A˚ for 371 C positions).
CTD. Interestingly, this proline is highly conserved The final model has an R value of 22.8% for all 20-2.1 A˚ data, which
was validated with a free R value of 27.3% monitored using a 5%among N-terminal segments of chemokine receptors.
reflection test set. The refined atomic model of M3 comprises theThe coincident use of a Pro residue that tightly packs
entire mature protein with the exception of the first 11 N-terminalagainst the completely conserved chemokine disulfide
residues (residues 12–382).by both chemokine receptors and M3 suggests a novel
strategy for the development of chemokine antagonists.
Crystallization and Structure Determination
One of the hallmarks of both acute and chronic inflam- of the M3/MCP-1(P8A) Complex
matory disorders is the excessive recruitment of leuko- The human MCP-1 variant MCP-1(P8A) was produced in E. coli and
cytes, a process mediated by chemokines. A number harbors the mutations P8A and M64I (Paavola et al., 1998). Crystals
of the M3/MCP-1(P8A) complex at 15 mg/ml were grown using aof autoimmune diseases are associated with chronic
slight molar excess of chemokine with 14% PEG4K, 200 mM NaAce-inflammation, and there has been considerable interest
tate [pH 4.1], and 100 mM MgCl2. Crystals of the complex belonglately in the development of chemokine antagonists for
to the P321 space group, with one SeMet labeled M3 and one MCP-their treatment (Proudfoot, 2002). In model systems, the
1(P8A) molecule in the asymmetric unit. MAD data were collected
poxvirus chemokine-inhibitor vCCI has shown promise on beamline X25 at NSLS at four wavelengths spanning the Se
in the treatment of allergen-induced asthma (Dabbagh absorption edge (Table 1). Se positions were located using molecu-
et al., 2000), while M-T7 can mitigate inflammatory-cell lar replacement phases obtained from uncomplexed M3 coordinates
and AMORE (CCP4, 1994). Model building was initiated on coordi-invasion after vascular injury (Liu et al., 2000). The M3
nates of M3 and MCP-1 (pdb entry 1DOK), which were docked intodecoy receptor is capable of sequestering members of
solvent flattened MAD electron density maps obtained using CNS.all four chemokine families and yet maintains a degree of
The model was refined against data merged and scaled from allselectivity. Our structural results have revealed several
four wavelengths, which for 149857(11156 unique) reflections was
mechanisms underlying M3 function that are potentially 98.3% (97.9) complete to 2.8 A˚ resolution with Rsym of 8.8(42.2)
exploitable. Thus, the structural and biophysical charac- and I of 14.5(4.8) (parentheses indicate outer shell 2.97–2.8). The
terization of the M3 decoy receptor presented here pro- final model has an R-value of 20.1% for all 20-2.8 A˚ data (R-free of
28.2%). The refined atomic model of the M3/MCP-1(P8A) complexvides an excellent framework for the rational design of
comprises residues 12–382 of M3 and 8–71 of MCP-1(P8A), withanti-inflammatory therapeutics focused on the potent
the first 7 and last 5 residues not observed. Although there are onlyand selective abrogation of chemokine networks.
one M3 and one MCP-1(P8A) molecule per ASU, a tightly associated
2:2 dimeric complex is created by the P321 2-fold symmetry axis.Experimental Procedures
Native PAGEBaculovirus Production of HV68 M3 and SeMet Labeled M3
Samples containing varying molar ratios of M3 and MCP-1(wt) wereBaculovirus harboring the entire unmodified M3 ORF were used to
infect Sf9 insect cells at 27C in serum-free CCM3 medium lacking run on native PAGE. Samples were mixed with M3 at 1.5 mg/ml and
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four different chemokine concentrations then incubated for 15 min. (1980). Isolation of five strains of herpesviruses from two species
of free living small rodents. Acta Virol. 24, 468.Separations were carried out with a 20% polyacrylamide gel run on
a PhastSystem and visualized using Coomassie blue staining. Note Bridgeman, A., Stevenson, P.G., Simas, J.P., and Efstathiou, S.
that MCP-1 runs completely off the gel and is not stained. Identical (2001). A secreted chemokine binding protein encoded by murine
native PAGE results as presented here were obtained using com- herpesvirus-68 is necessary for the establishment of a normal la-
plexes of M3 with MCP-1(P8A). tent load. J. Exp. Med. 194, 301–312.
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P.,
Size Exclusion Chromatography Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M.,
Size Exclusion Chromatography (SEC) was used to determine the Pannu, N.S., et al. (1998). Crystallography & NMR system: a new
size of M3 alone and in complex with MCP-1 or the mutant MCP- software suite for macromolecular structure determination. Acta
1(P8A). Protein samples (0.5 mls at 1–2 mg/ml) were loaded onto Crystallogr. D Biol. Crystallogr. 54, 905–921.
an AKTA FPLC system equipped with a HiLoad 26/60 Superdex 200
Carfi, A., Smith, C.A., Smolak, P.J., McGrew, J., and Wiley, D.C.column. Standards and samples were run with a flow rate of 2.0 ml/
(1999). Structure of a soluble secreted chemokine inhibitor vCCImin. The calibration curve was prepared using molecular weight
(p35) from cowpox virus. Proc. Natl. Acad. Sci. USA 96, 12379–standards from the LMW and HMW Gel Filtration Calibration Kits
12383.(Amersham Pharmacia Biotech). M3/chemokine complexes con-
Carson, M. (1997). Ribbons. Methods Enzymol. 277, 493–505.tained a 4-fold excess of the chemokine being examined in order
to visualize the elution of both the complex and the free chemokine. CCP4 (Collaborative Computational Project 4) (1994). The CCP4
suite: programs for protein crystallography. Acta Crystallogr. D 50,
Dynamic Light Scattering 760–763.
DLS experiments were performed using a DynaPro-801TC molecular Clark-Lewis, I., Kim, K.S., Rajarathnam, K., Gong, J.H., Dewald, B.,
sizing instrument (Protein Solutions, Inc.). Measurements were con- Moser, B., Baggiolini, M., and Sykes, B.D. (1995). Structure-activity
ducted with protein at 1 mg/ml at 20C in PBS. M3/chemokine com- relationships of chemokines. J. Leukoc. Biol. 57, 703–711.
plexes were prepared using equal molar ratios. BSA samples at 1
Dabbagh, K., Xiao, Y., Smith, C., Stepick-Biek, P., Kim, S.G., Lamm,mg/ml were run as a control. Average hydrodynamic scattering radii
W.J., Liggitt, D.H., and Lewis, D.B. (2000). Local blockade of allergicfor the samples were calculated from monomodal fits of 20 measure-
airway hyperreactivity and inflammation by the poxvirus-derivedments. Molecular weights were estimated based on a model of a
pan-CC-chemokine inhibitor vCCI. J. Immunol. 165, 3418–3422.spherical globular protein of the measured hydrodynamic radius.
de Vos, A.M., Ultsch, M., and Kossiakoff, A.A. (1992). Human growth
hormone and extracellular domain of its receptor: crystal structureMutant Chemokine Binding Assay
of the complex. Science 255, 306–312.Competitive inhibition binding to M3 was investigated for several
Fremont, D.H., Crawford, F., Marrack, P., Hendrickson, W.A., andAla substituted variants of MCP-1. Binding was demonstrated by
Kappler, J. (1998). Crystal structure of mouse H2-M. Immunity 9,incubating 250 pM of baculovirus produced M3 with 500 pM of
385–393.125I-hRANTES and increasing amounts of unlabeled mutant MCP-1.
Samples were incubated with anti-M3 polyclonal sera, and then Garcia, K.C., Teyton, L., and Wilson, I.A. (1999). Structural basis of
pulled down with protein A conjugated agarose beads, which were T cell recognition. Annu. Rev. Immunol. 17, 369–397.
washed and resuspended in scintillation fluid. Measurements were Graham, K.A., Lalani, A.S., Macen, J.L., Ness, T.L., Barry, M., Liu,
determined in triplicate and repeated in at least two independent L.Y., Lucas, A., Clark-Lewis, I., Moyer, R.W., and McFadden, G.
experiments. The percentage of maximal binding (mean  SEM) (1997). The T1/35kDa family of poxvirus-secreted proteins bind che-
refers to binding in the absence of competitor, with the average mokines and modulate leukocyte influx into virus-infected tissues.
value of maximal binding measured as 50,000 cpm. Virology 229, 12–24.
Hayward, S., and Berendsen, H.J. (1998). Systematic analysis ofPreparation of Figures
domain motions in proteins from conformational change: new re-Figures were prepared with the programs ALSCRIPT (Barton, 1993),
sults on citrate synthase and T4 lysozyme. Proteins 30, 144–154.GRASP (Nicholls et al., 1993), and Ribbons (Carson, 1997). Buried
Hemmerich, S., Paavola, C., Bloom, A., Bhakta, S., Freedman, R.,surface accessible areas were calculated using CNS (Brunger et al.,
Grunberger, D., Krstenansky, J., Lee, S., McCarley, D., Mulkins, M.,1998). Hydrogen bonding and van der Waal contacts were enumer-
et al. (1999). Identification of residues in the monocyte chemotacticated with HBPLUS (McDonald and Thornton, 1994). Domain motions
protein-1 that contact the MCP-1 receptor, CCR2. Biochemistry 38,were calculated using DynDom (Hayward and Berendsen, 1998).
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